Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day. World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. In an effort to drive awareness and […]
abbott
Abbott rolls out National Diabetes Awareness Month initiative to promote CGM use
Abbott (NYSE:ABT) announced today that it launched its new “Countdown at a Crossroads” initiative for National Diabetes Awareness Month. The initiative sees Abbott take over the Oculus Center in New York City with an animated installation promoting diabetes awareness. This installation features the faces and stories of people impacted by diabetes, including comedian and talk […]
How Abbott developed an accessible, affordable CGM — the FreeStyle Libre system
According to Abbott Diabetes DVP, Technical Operations, Marc Taub, one in nine people in the U.S. live with diabetes. Speaking at DeviceTalks West in Santa Clara, California, he said that means everyone in the room at the time knows someone with diabetes. The condition requires constant attention and management, something Taub and Abbott aim to alleviate. […]
Abbott has positive data for Esprit drug-eluting resorbable scaffold
Abbott [WtwhTicker symbol=”ABT”](NYSE: ABT)[/WtwhTicker] today announced data supporting its Esprit BTK everolimus-eluting resorbable scaffold system. The company designed Esprit BTK to treat people with chronic limb-threatening ischemia (CLTI), a severe stage of peripheral artery disease (PAD). Abbott said its LIFE-BTK trial met both of its primary safety and effectiveness endpoints. It demonstrated the reduction of […]
Abbott updates FreeStyle Libre 2 app with silent alarm mode
Abbott (NYSE:ABT) announced today that it released a new FreeStyle Libre 2 app version with fully customizable alarms. The updated app release for the Abbott continuous glucose monitor (CGM) system — version 2.7.5 — features silent mode. This enables people with diabetes to use their CGM with less interruptions throughout the day. Silent mode delivers […]
Abbott study says FreeStyle Libre users on insulin show lower HbA1c levels
Abbott (NYSE:ABT) today announced real-world data associating its FreeStyle Libre CGM with significant HbA1c reductions. The continuous glucose monitor (CGM) played a part in significant reductions in HbA1c, the average glucose levels over a three-month period. It was also associated with a lower rate of hospitalization for people with type 2 diabetes on both multiple […]
Abbott: Real-world data indicates GLP-1s could be accelerator for FreeStyle Libre
New real-world data from Abbott (NYSE:ABT) demonstrates a potentially positive impact of GLP-1 drugs on diabetes technology. GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss. The drug class continues to […]
Abbott completes Bigfoot Biomedical acquisition
Abbott (NYSE:ABT) announced today that it completed its previously announced acquisition of Bigfoot Biomedical. Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms. Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management […]
Abbott, WeightWatchers unveil connected diabetes app
Abbott (NYSE:ABT) and WeightWatchers today announced the availability of a connected app for people living with diabetes. In August 2022, the companies announced a collaboration to integrate continuous glucose monitoring (CGM) with the WW diabetes-tailored plan. The integrated offering provides a mobile experience with information and insights needed for those with diabetes. It helps to […]
Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs
Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]